Biomedical

Alexandria Real Estate Equities completed construction in November of 2023 on Moderna's global headquarters at One Kendall Square. Designed by NBBJ to be the most sustainable lab building in Cambridge, the 462,100-rsf facility will support the development of innovative mRNA vaccines and therapies. The Class A+ property integrates advanced R&D labs and offices with engaging gathering spaces to promote interaction and collaboration.

The University of California, San Francisco is planning to construct the $842 million Research and Academic Building on its Parnassus Heights campus. Designed by HGA and Snøhetta to foster interdisciplinary exchange and discovery, the 300,000-gsf facility will provide advanced laboratories for programs in oncology, microbiology, immunology, and cell biology.

Evergreen Bioscience Innovation Cluster is planning to construct a 77,000-sf research center in Spokane. Designed by ALSC Architects, the four-story facility will offer 55,000 leasable square feet of space where growing companies can engage in collaborative discovery. State-of-the-art wet labs supported by robust infrastructure will accelerate the discovery of new therapies, complemented by a range of collaboration spaces and office environments. 

The University of Texas MD Anderson Cancer Center broke ground in late September of 2023 on the $668 million South Campus Research Building 5 in Houston. Designed by Elkus Manfredi Architects to catalyze biomedical discovery and innovation, the 600,000-sf structure will anchor the institutions's R&D campus at the Texas Medical Center's Helix Park. Housing the James P.

University of Chicago Medicine broke ground in September of 2023 on an $815 million cancer center that will provide world-class environments for research and treatment. CannonDesign's architectural vision for the freestanding facility will radically elevate the patient experience by bringing together clinicians, investigators, and physician-scientists to optimize the delivery of team-based care.

Trammell Crow Company will begin construction in late 2023 on a 234,000-sf life sciences center in Redwood City, Calif. Created in collaboration with joint venture partner CBRE Investment Management, the five-story facility will offer Class A lab and office environments for biomedical tenants. Advanced building systems will reduce carbon emissions while accommodating the demands of next-generation research programs, with sophisticated HVAC infrastructure supplying 100 percent outside air to enhance occupant wellbeing. 

The University of Texas at Dallas and UT Southwestern opened the $120 million Texas Instruments Biomedical Engineering and Sciences Building in August of 2023. Located on the east campus of UT Southwestern Medical Center, the 150,000-sf facility accommodates innovative research programs in artificial intelligence, robotics, and molecular and genetic engineering. The five-story structure provides state-of-the-art wet labs, dry labs, and collaboration spaces where multidisciplinary teams will discover new medical solutions and technologies.

Ancora L&G began construction in August of 2023 on a $195 million life sciences center in Providence that will provide 80,000 sf of world-class research space for the Rhode Island Department of Health. Occupying the entirety of the second and third floors, the new state health lab will feature BSL-3 suites for the detection and mitigation of infectious disease agents and environmental hazards.

McCord Development is planning to construct BioHub Two in northeast Houston. Comprising 500,000 sf of lab, office, and cGMP manufacturing space, the 45-acre campus will accommodate a total of seven structures offering built-to-suit environments for private companies. This dynamic nexus of innovation and discovery will catalyze synergies with San Jacinto College's planned Biotech Training Center, which will be located nearby.

Canary Wharf Group and Kadans will break ground in fall of 2023 on One North Quay, a £500 million life sciences center in London. Designed by KPF, the 823,000-sf tower will provide world-class lab and office environments for biomedical and pharmaceutical companies. Constructed to the highest technological standards, the 23-story vertical campus will leverage advanced infrastructure to accommodate the stringent demands of wet-bench chemistry and high-containment research programs.

Moderna is investing $322 million to create a state-of-the-art biomanufacturing center in Marlborough, Mass. Offering leading-edge environments for the production of innovative therapies and vaccines, the state-of-the-art facility will also include a cleanroom, labs, offices, and warehouse areas. The project involves the renovation of a two-story, 140,000-sf building that was purchased in spring of 2023 from Oxford Properties. Sited on 24 acres, the existing structure will be expanded to provide an additional 60,000 sf of space. 

CellCarta, a leading provider of medical laboratory services, is partnering with developer Jadco to create a 450,000-sf life sciences center in Montreal. The $350 million project will transform the former site of the Montreal Chest Institute into Inspire Bio Innovations, a biomedical hub that will catalyze the development of new therapies and precision medicine technologies.

The New Brunswick Development Corporation began construction in early summer of 2023 on the first phase of the HELIX innovation district. Catalyzing regional synergies in medical research, education, and healthcare, the $750 million project will accommodate tenants including Rutgers University, RWJBarnabas Health, Hackensack Meridian Health, and Princeton University. The 12-story, 573,400-sf structure will strategically collocate three key elements.

Ultragenyx opened a 110,000-sf gene therapy manufacturing facility in June of 2023 in Bedford, Mass. Advancing the creation of innovative treatments for rare genetic diseases, the sophisticated structure enables the large-scale manufacture of clinical-stage materials and approved products based on adeno-associated viral vectors (AAV). The highly efficient building integrates the company's proprietary Pinnacle PCL™ (producer cell line) platform which delivers optimal quality and scalability while reducing costs.

The Australian Institute for Infectious Disease (AIID) is planning to construct a state-of-the-art translational research facility in the Melbourne Biomedical Precinct. The Doherty Institute, the Burnet Institute, and the University of Melbourne are the founding partners for the AUD$650 million project, which will accommodate over 1,000 scientists, academics, professionals, and public health experts engaged in collaborative discovery.